Used primarily in the treatment of advanced prostate cancer, this compound combines estrogenic and cytotoxic properties to inhibit tumor growth. It interferes with microtubule function, disrupting cell division in cancer cells. The agent is particularly effective in cases where the cancer has become resistant to standard hormonal therapies. It is administered orally and is often considered when other treatment options have limited effectiveness. Its dual mechanism helps reduce tumor progression and alleviate symptoms associated with metastatic prostate cancer.